For patients with benign brain tumors, the promise of proton beam therapy lies in physics: protons deposit most of their energy at a precise depth, delivering a Bragg peak at the tumor while sparing healthy tissue downstream, unlike conventional photon radiotherapy, which continues to irradiate tissue beyond the target. For individuals facing decades of survival after treatment for slow-growing tumors such as meningiomas, minimizing the radiation dose to uninvolved brain and adjacent critical structures is not merely a technical nicety but a question of long-term neurological, cognitive and endocrine function. Yet the long-term lived experience of these patients—their fatigue, sleep, cognition, and overall quality of life years after their last treatment session—has remained strikingly underdocumented. A new prospective study from Sweden, published in the Journal of Neuro-Oncology, now offers one of the longest patient-reported follow-ups to date, tracking health-related quality of life in a predominantly meningioma cohort for a full five years after proton beam therapy, and its findings paint a picture that is at once reassuring and sobering.
The study, conducted within the multicentre ProtonCare research program and led by Per Fessé of the University of Gothenburg together with colleagues across Swedish institutions, enrolled 126 adults treated with proton beam therapy at the Skandion Clinic in Uppsala, Sweden’s national proton therapy center, between August 2015 and October 2018. The cohort consisted overwhelmingly of patients with meningiomas—the most common primary intracranial tumors in adults, occurring more frequently in women and generally associated with favorable survival—alongside smaller numbers of patients with other benign intracranial or sellar-region tumors such as vestibular schwannomas, pituitary adenomas and craniopharyngiomas. Participants completed two validated patient-reported outcome instruments at baseline before treatment and at repeated intervals extending to 60 months: the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30, a general cancer quality-of-life questionnaire covering functional and symptom scales, and its brain tumor-specific module, the QLQ-BN20, which probes domains such as drowsiness, motor dysfunction, bladder control, communication deficits and future uncertainty.
The statistical approach deserves attention because it shapes the reliability of the conclusions. The researchers used mixed models for repeated measures (MMRM), a framework that exploits every available observation across all time points rather than discarding patients who missed visits, modeling each score as a function of visit with the baseline score as a covariate and accounting for within-subject correlation through a first-order autoregressive covariance structure. Missing data were handled under a Missing At Random assumption using likelihood-based estimation, with degrees of freedom computed via the Kenward-Roger method. For change-from-baseline comparisons, the team supplemented the MMRM results with paired analyses among the 77 participants (61 percent) who completed the five-year assessment, using Fisher’s non-parametric permutation tests and paired t-tests. Critically, the investigators interpreted change magnitudes against established minimum important differences: changes of roughly 5 to 10 points on the 0-to-100 EORTC scales were considered potentially clinically relevant, while changes of at least 10 points were considered clearly meaningful, following thresholds established for the QLQ-C30 and brain tumor-specific anchors.
Against these benchmarks, the five-year results revealed a distinctly mixed pattern. Global health status—the patient’s overall self-assessment of health and quality of life—declined only slightly and not statistically significantly, by 2.2 points (95 percent confidence interval −5.8 to 1.3; p = 0.22), suggesting that most patients maintained their fundamental sense of well-being over the long term. However, the QLQ-C30 summary score, a composite integrating functioning and symptom scales, declined by 4.4 points (95 percent CI −6.1 to −2.7; p < 0.001), a statistically robust though sub-threshold decrease. The most prominent deterioration appeared in two symptoms that reached the clear clinical relevance threshold: fatigue increased by 11.1 points (95 percent CI 7.4 to 14.8; p < 0.001) and insomnia by 10.6 points (95 percent CI 5.4 to 15.8; p < 0.001). Smaller but statistically significant worsening was recorded for pain (+8.1), constipation (+8.0) and dyspnoea (+5.9), all falling within the potentially relevant range.
The functioning domains told a complementary story. Physical functioning declined by 5.7 points (95 percent CI −7.9 to −3.5; p < 0.001) and cognitive functioning—assessed through patient-reported items concerning concentration and memory—by 6.0 points (95 percent CI −9.5 to −2.6; p < 0.001), changes the authors characterized as both statistically significant and potentially clinically relevant. Emotional functioning, in contrast, improved modestly by 4.3 points (p = 0.008), a finding the researchers cautiously attribute to psychological adaptation, response shift, or the relief of surviving and recovering, although they note its clinical relevance remains uncertain. Financial difficulties remained low and essentially unchanged, a result the authors situate within Sweden’s predominantly tax-funded healthcare system with universal coverage, while acknowledging that reduced work capacity and income effects can nonetheless persist and that the finding may not generalize to systems where patients bear greater out-of-pocket costs.
The brain tumor-specific QLQ-BN20 module added granular detail on symptoms particularly relevant to this population. Hair loss increased by 11.4 points (95 percent CI 7.1 to 15.7; p < 0.001), crossing the clearly clinically meaningful threshold—a notable and somewhat surprising finding given that proton therapy is often assumed to reduce such visible toxicities, and one that may reflect field location, dose distribution or the temporal accumulation of effects. Drowsiness rose by 9.3 points, bladder control difficulties by 7.5 points, itchy skin by 7.6 points, motor dysfunction by 6.7 points, weakness of the legs by 6.3 points and communication deficits by 5.0 points, all statistically significant. Headaches, encouragingly, decreased by 5.0 points (p = 0.028), while future uncertainty, seizures and visual disorders showed no evidence of long-term group-level change. Exploratory regression analyses found that older age was associated with greater deterioration in role functioning (β −6.90 per decade; p = 0.041) and social functioning (β −7.73 per decade; p = 0.0048), and that being outside employment was linked to larger declines in these same domains, whereas no investigated sociodemographic factor—including sex, age, marital status, occupation or education—was associated with the five-year change in fatigue or insomnia.
Interpreting these findings requires careful consideration of what can and cannot be attributed to proton therapy itself, a limitation the authors confront directly. Without a photon-treated comparison group, the study describes outcomes after proton beam therapy rather than effects of it. The observed fatigue, insomnia and cognitive decline may reflect a confluence of factors: ageing, comorbidity, medication, reduced physical activity, endocrine dysfunction, persistent tumor- or surgery-related morbidity, and late radiation effects, none of which could be fully disentangled with the data collected. Fatigue and sleep disturbance are known to interact with subjective concentration and memory complaints, and the coexistence of stable global health status with domain-level deterioration may partly reflect adaptation and response shift—phenomena well documented in long-term cancer survivors, including qualitative work within the same Swedish cohort in which patients described acceptance, altered routines, and reliance on family support while living with persistent fatigue and reduced autonomy. Selective attrition further complicates the picture: the 49 patients who did not complete the five-year assessment were slightly younger, more often male, more often living alone, and more often carried diagnoses other than meningioma, and six had died by follow-up for reasons that were unknown.
These caveats notwithstanding, the study’s clinical implications are concrete. The convergence of clinically meaningful fatigue and insomnia with declining physical and cognitive functioning and worsening mobility, bladder and communication symptoms argues, the authors contend, for structured long-term follow-up and rehabilitation services tailored to this survivor population—encompassing not only neurological surveillance but also sleep interventions, fatigue management, cognitive support, and assessment of urinary and motor symptoms. That role and social functioning deteriorated more among older participants and those outside employment suggests psychosocial rehabilitation needs are unevenly distributed. Because meningioma patients typically face decades of survival, even modest average declines in quality of life translate into a substantial cumulative burden, and identifying which patients deteriorate—and why—remains a central unanswered question.
The research also lands amid an ongoing debate in radiation oncology about the appropriate role of proton therapy for benign intracranial tumors. Evidence indicates tumor control rates comparable to advanced photon techniques, and dosimetric studies consistently demonstrate reduced integral dose and sparing of uninvolved brain, which is precisely the rationale for choosing protons in patients with long life expectancies and lesions near critical structures such as the optic pathways, brainstem and hypothalamic-pituitary axis. Potential benefits are thought most relevant to late effects—neurocognitive, endocrine, sensory and vascular—but current clinical evidence remains insufficient to predict the direction or magnitude of differences in individual patient-reported symptoms between proton and photon modalities. Restricted availability, range uncertainty inherent to proton physics in heterogeneous tissue, and the scarcity of randomized comparative data continue to limit definitive claims, and clinician-assessed long-term toxicity after proton therapy for meningioma has been reported in up to 54 percent of patients in prior series.
Methodologically, the study adhered to STROBE reporting guidelines and the SISAQOL international standards for analyzing patient-reported outcome endpoints, and its prospective design with repeated assessments through five years, validated instruments, and pre-specified clinically interpretable thresholds represent meaningful strengths in a literature dominated by retrospective surveys and short-term mixed-cohort analyses. The authors also transparently acknowledge limitations: the two-item assessment of cognition captures only a slice of a complex domain, detailed data on radiation dose, target volumes, medication, endocrine factors and comorbidities were lacking, sick-leave data were not collected, and the multiplicity of exploratory associations raises the possibility of chance findings. The near-total dominance of meningioma in the cohort, while a strength for interpretability, precluded reliable comparisons across diagnostic subtypes.
Ultimately, the study delivers a message that is neither triumphalist nor alarming. Five years after proton beam therapy, most patients in this Swedish cohort rated their global health as stable, headaches had eased, and emotional functioning had improved—yet fatigue, insomnia and a constellation of functional and tumor-specific symptoms had measurably worsened, and overall quality of life had declined modestly. For the growing population of long-term survivors of benign brain tumors, and for the clinicians who follow them, the findings argue that the finish line of treatment is not the end of the story: structured surveillance and rehabilitation extending well beyond five years may be essential to addressing the durable symptom burden these data reveal, and comparative studies against photon therapy remain the critical next step for establishing what, exactly, proton therapy buys these patients in the decades that follow.
Subject of Research: Five-year changes in health-related quality of life and brain tumor-specific symptoms in a primarily meningioma cohort treated with proton beam therapy
Subject of Research: Cancer
Article Title: Five-year changes in health-related quality of life after proton therapy in a primarily meningioma cohort: a prospective study
Article References: Fessé, P., Åkeflo, L., Ahlberg, K., Blomqvist, E., Fransson, P., Kristensen, I., Kunni, K., Langegård, U., Ohlsson-Nevo, E., & Sjövall, K. (2026). Five-year changes in health-related quality of life after proton therapy in a primarily meningioma cohort: a prospective study. Journal of Neuro-Oncology, 179(2), Article 49. https://doi.org/10.1007/s11060-026-05767-1
Image Credits: AI Generated
DOI: 10.1007/s11060-026-05767-1
Keywords: proton beam therapy, meningioma, health-related quality of life, patient-reported outcomes, EORTC QLQ-C30, EORTC QLQ-BN20, fatigue, insomnia, benign brain tumors, long-term follow-up, prospective cohort study, neuro-oncology
Cite Scienmag News
APA
MLA
Chicago
Nathaniel Bowman. (September 7, 2026). Proton therapy sustains quality of life in meningioma patients over five years. Scienmag. https://scienmag.com/proton-therapy-sustains-quality-of-life-in-meningioma-patients-over-five-years/
Nathaniel Bowman. “Proton therapy sustains quality of life in meningioma patients over five years.” Scienmag, 7 September 2026, https://scienmag.com/proton-therapy-sustains-quality-of-life-in-meningioma-patients-over-five-years/. Accessed 7 September 2026.
Nathaniel Bowman. “Proton therapy sustains quality of life in meningioma patients over five years.” Scienmag. September 7, 2026. https://scienmag.com/proton-therapy-sustains-quality-of-life-in-meningioma-patients-over-five-years/
Copy citation
Download RIS
Tags: benefits of proton therapy over photon radiotherapybenefits of proton therapy versus photon radiotherapyfatigue and sleep quality in meningioma patientshealth-related quality of life in brain tumor survivorsimpact of proton therapy on endocrine functionlong-term effects of proton therapy on brain healthlong-term patient-reported outcomes in brain tumor survivorslong-term quality of life after brain tumor treatmentlong-term quality of life in meningioma patientslong-term survivorship and quality of life in slowminimizing radiation damage in meningioma treatmentminimizing radiation exposure to healthy brain tissueneuro-oncology treatment advancementsneuroendocrine function after proton therapypatient-reported outcomes in proton therapypreservation of neurological and cognitive function after proton treatmentpreservation of neurological and cognitive function in benign brain tumorsprospective studies on proton therapyProton beam therapy for benign brain tumorsProton beam therapy for meningiomaSwedish prospective study on proton therapy outcomes
